A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Plain-language guide to NCT06745284: phase 1 randomized trial of Semaglutide and Survodutide, 64 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06745284
Phase: phase 1
Status: active, not recruiting
Start: 2025-03-26
Completion (planned or actual): 2027-01-08
Participants: 64 (actual)
Design: randomized, open label (everyone knows who gets what), treatment
Conditions studied: Obesity
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

The trial (phase 1) is built around Semaglutide and Survodutide.

This study is open to adults between 18 and 65 years of age who have obesity.

People can join the study if they have a body mass index (BMI) between 30 and 45 km/m².

It had two arms (groups): Survodutide arm (experimental) and Semaglutide arm (active comparator).

The registry classes the interventions as drug.

Who Took Part

64 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age of 18 to 65 years (inclusive). Male or female subjects with obesity (defined as a body mass index (BMI) of ≥30 and ≤45 kg/m²). In the investigator's opinion, are well-motivated, capable, and willing to:.

The full record lists 7 inclusion and 6 exclusion criteria; among the exclusions: history of chronic liver disease / cirrhosis; medications for obesity (including over-the-counter medications) within 3 months before visit 1 (screening).

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

It started in 2025-03-26 with completion listed for 2027-01-08.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Semaglutide and Survodutide in 64 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page and the Survodutide compound page, all human trials.

Our Notes on the Compounds

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Survodutide: An investigational long-acting GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.